Should you buy Zevra Therapeutics (ZVRA)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
ZVRA currently trades above the base anchor, in the upper half of the engine methodology range.
Engine methodology range — mechanically derived from pipeline gate outputs + peer-multiple inputs. Not an analyst price target. JSON-LD emission gated pending counsel review.
What the engine is tracking
- Deep Value Margin Of Safety—
- Elite Quality Compounder Metrics→Stable
- Earnings Beat Streak Momentum→Stable
- +1 more pillar — see the Why tab for full reasoning
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Deep Value Margin Of Safety
Trip ifMargin of safety compresses below 20% from the current 54%.
- P2Elite Quality Compounder Metrics
Trip ifFree cash flow to net income ratio falls below 10% from the current 21%.
- P3Earnings Beat Streak Momentum
Trip ifMiss count rises to 2 or more out of the next 4 quarters.
- P4Insider Selling High Short Interest Risk
Trip ifShort interest falls below 5% from the current 11%.
How the engine reached this verdict
TrendMatrix's engine output for Zevra Therapeutics, Inc. (ZVRA) is STRONG_BUY_WAIT with high conviction, score 7.0/10 at $10.43. The engine flags WAIT: the structural case holds but the entry-asymmetry math improves at lower prices.
The engine's suggested entry zone is $9.97, currently 4.6% above entry. Target $21.97, stop $9.27, asymmetric R:R 11.89. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 1.7% of portfolio at this asymmetry level (high-conviction tier).
On the bull side: V7 flight-to-quality bonus: +0.5 (Q=8.7 in RISK_OFF); Sector modifier (Healthcare): +0.5; Strong earnings beat streak (4/4). On the bear side: Concentration risk — Product: MIPLYFFA (82.0%); Earnings in 5 days (event risk); Elevated risk factors. Active engine warnings: V9 Gate blocked BUY_NOW: Earnings in 5 days (≤7d hard window), V9 Gate Failed: EARNINGS_PROXIMITY:5d<=7d.
BUY_NOW requires earnings proximity (5d<=7d) to clear OR price pulling back to the entry zone of $9.97 with asymmetry crossing 2.5. The verdict flips to HOLD if overall score deteriorates by ~0.7 from sentiment or technical drift.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ZVRA — 10-dimension breakdown →
Bull case
- ▸V7 flight-to-quality bonus: +0.5 (Q=8.7 in RISK_OFF)
- ▸Sector modifier (Healthcare): +0.5
- ▸Strong earnings beat streak (4/4)
Bear case
- ▸Concentration risk — Product: MIPLYFFA (82.0%)
- ▸Earnings in 5 days (event risk)
- ▸Elevated risk factors